Correspondence | Published:

Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor

Bone Marrow Transplantationvolume 53pages13511355 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44:453–5.

  2. 2.

    Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–13.

  3. 3.

    Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76–98.

  4. 4.

    Coen DM. Antiviral drug resistance. Ann N Y Acad Sci. 1990;616:224–37.

  5. 5.

    Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.

  6. 6.

    Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, et al. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. J Transl Med. 2014;12:336.

  7. 7.

    Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhoff B, et al. Comparative analysis of clinical-scale ifn-gamma-positive T-cell enrichment using partially and fully integrated platforms. Front Immunol. 2016;7:393.

  8. 8.

    Banas B, Steubl D, Renders L, Chittka D, Banas MC, Wekerle T, et al. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. 2018;31:436–50.

  9. 9.

    Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, et al. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Biol Blood Marrow Transplant. 2013;19:1480–92.

  10. 10.

    Gendzekhadze K, Gaidulis L, Senitzer D. Chimerism testing by quantitative PCR using Indel markers. Methods Mol Biol. 2013;1034:221–37.

  11. 11.

    Koldehoff M, Steckel NK, Hlinka M, Beelen DW, Elmaagacli AH. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol. 2006;81:735–46.

  12. 12.

    Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35:185–93.

  13. 13.

    Lindemann M, Barsegian V, Runde V, Fiedler M, Heermann KH, Schaefer UW, et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation. 2003;75:833–8.

Download references


We are grateful to Monika Huben, Anja König, Nicole Neuman, Martina Praast, and Dörthe Rokitta for their excellent technical assistance.

Author contributions

D.W.B., B.E.V., M.L., R.B., and M.K. were involved in the conception and design of the study. M.K., N.K.S., V.K., and D.W.B. provided the samples. M.L., M.K., B.M.K., M.F., and A.H. were involved in the collection and assembly of data. B.E.V., B.M.K., and R.B.L. were involved in the donor selection, quality control of the CMV-VSTs, and the final release of the T-cell product. M.L. and M.K. were involved in data analysis and interpretation. M.L., M.K., and P.H.O. wrote the manuscript. All the authors gave final approval of the manuscript.

Author information


  1. Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany

    • Monika Lindemann
    • , Andreas Heinold
    •  & Peter A. Horn
  2. Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany

    • Britta Eiz-Vesper
    • , Sabine Tischer
    •  & Rainer Blasczyk
  3. Department of Bone Marrow Transplantation, University Hospital Essen, University Duisburg-Essen, Essen, Germany

    • Nina K. Steckel
    • , Vesna Klisanin
    • , Dietrich W. Beelen
    •  & Michael Koldehoff
  4. Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

    • Melanie Fiedler
  5. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

    • Britta Maecker-Kolhoff


  1. Search for Monika Lindemann in:

  2. Search for Britta Eiz-Vesper in:

  3. Search for Nina K. Steckel in:

  4. Search for Sabine Tischer in:

  5. Search for Melanie Fiedler in:

  6. Search for Andreas Heinold in:

  7. Search for Vesna Klisanin in:

  8. Search for Britta Maecker-Kolhoff in:

  9. Search for Rainer Blasczyk in:

  10. Search for Peter A. Horn in:

  11. Search for Dietrich W. Beelen in:

  12. Search for Michael Koldehoff in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Monika Lindemann.

About this article

Publication history